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ABSTRACT
Patients affected by Duchenne muscular dystrophy (DMD) and dystrophic MDX mice were investigated in this study for their bone
phenotype and systemic regulators of bone turnover. Micro–computed tomographic (mCT) and histomorphometric analyses showed
reduced bone mass and higher osteoclast and bone resorption parameters in MDX mice compared with wild-type mice, whereas
osteoblast parameters and mineral apposition rate were lower. In a panel of circulating pro-osteoclastogenic cytokines evaluated in the
MDX sera, interleukin 6 (IL-6) was increased compared with wild-type mice. Likewise, DMD patients showed low bone mineral density
(BMD) Z-scores and high bone-resorption marker and serum IL-6. Human primary osteoblasts from healthy donors incubated with 10%
sera from DMD patients showed decreased nodule mineralization. Many osteogenic genes were downregulated in these cultures,
including osterix and osteocalcin, by a mechanism blunted by an IL-6-neutralizing antibody. In contrast, the mRNAs of osteoclastogenic
cytokines IL6, IL11, inhibin-bA, and TGFb2 were increased, although only IL-6 was found to be high in the circulation. Consistently,
enhancement of osteoclastogenesis was noted in cultures of circulating mononuclear precursors from DMD patients or from healthy
donors cultured in the presence of DMD sera or IL-6. Circulating IL-6 also played a dominant role in osteoclast formation because ex vivo
wild-type calvarial bones cultured with 10% sera of MDX mice showed increase osteoclast and bone-resorption parameters that were
dampen by treatment with an IL-6 antibody. These results point to IL-6 as an important mediator of bone loss in DMD and suggest that
targeted anti-IL-6 therapy may have a positive impact on the bone phenotype in these patients.  2011 American Society for Bone and
Mineral Research.
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Introduction
D
uchenne muscular dystrophy (DMD) is an X-linked disorder
owing to mutations in the gene encoding dystrophin.
(1) It
represents the most common muscular dystrophy in children,
affecting 1 in 3500 young males.
(2) Usually, the first symptom
is motor delay, but subsequently, cardiomyopathy and
respiratory insufficiency become apparent, leading to death in
early adulthood.
(3)
In skeletal muscle, dystrophin is localized especially at the
sarcolemma, assembled with several other glycoproteins, such
as dystroglicans, syntrophins, dystrobrevins, sarcoglycans, and
sarcospan, all together making the dystrophin glycoprotein
complex, whose integrity is critical for linking the actin
cytoskeleton to the extracellular matrix.
(4,5) Deficiency of
dystrophin expression affects formation of the dystrophin
glycoprotein complex, causing disruption of the molecular
bridge, with resulting membrane instability, increased suscepti-
bility to mechanical stress, and altered cellular metabolism.
(6–10)
Altogether, these events favor myofiber necrosis, which is
believed to be the pivotal trigger of the state of inflammation
that characterizes skeletal muscle in DMD patients. Indeed,
in DMD muscles, a chronic-type mononuclear cell infiltrate is
present early, before the onset of muscle weakness,
(11) and gene
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1891expression profiles show that the inflammatory response
dominates the molecular signature of dystrophin-deficient
muscles not only in humans but also in the dystrophin null
mouse, MDX, which is the most used murine model for this
disease.
(12,13) Therefore, a vast body of evidence supports a
pivotal role of inflammation in the progression of muscle
loss. However, the underlying molecular mechanisms are still
unclear.
Consistent with these observations, glucocorticoids, such as
prednisone or deflazacort, are the only drugs shown to be
effective for DMD treatment, and they delay the progressive loss
ofmusclestrengthandfunction.Itisgenerallybelievedthattheir
beneficial effects is secondary to their potent anti-inflammatory
action. However, long-term treatment with glucocorticoids
exposes patients to severe side effects, particularly on the
skeletal system.
(14–17)
Involvement of the skeletal system in DMD is very common.
Osteoporosis is observed in many patients, and up to a third of
them are affected by pathologic fractures of both long bones
and vertebrae.
(18,19) Fractures have a significant impact on
mobility and quality of life of patients, but the mechanisms
underlying the involvement of bone tissue in DMD are still
poorly understood. The literature is scarce of data related to
bone mass and metabolism in DMD patients,
(20,21) and it is still
unknown whether DMD by itself leads to a reduced accrual of
bone mineral density (BMD) independent of glucocorticoid
therapy.
In this study, we analyzed the bone phenotype of the MDX
mouse and evaluated the ability of sera collected from DMD
patients before the onset of glucocorticoid therapy and from
MDX mice to modulate osteoblast and osteoclast function. We
report that a cytokine imbalance appears to contribute to the
bone loss in DMD and point to interleukin 6 (IL-6) as a possible
systemic mediator of the damage induced by chronic
inflammation in bone, which could be subjected to therapeutic
neutralization.
Materials and Methods
Animals
MDX (X chromosome-linked muscular dystrophy) homozygous
mice (CB6F1/C57BL6 background) carrying a spontaneous
single-base mutation on exon 23 of the dystrophin gene
(22)
wereusedforanalysisofthebonephenotypeat6monthsofage.
Neonatal CD1 micewere used toisolate calvarial bones for organ
cultures.
Procedures involving animals and their care were conducted
in conformity with national and international laws and policies
(European Economic Community Council Directive 86/609,
Italian Legislative Decree 116/92, National Institutes of Health
Guide for the Care and Use of Laboratory Animals) and were
approved by our internal ethical board.
Mice were euthanized by cervical dislocation, and long
and parietal bones were removed, cleared of soft tissues, and
processed for micro–computed tomography (mCT), histology,
histomorphometry, and reverse-transcriptase polymerase chain
reaction (RT-PCR) analysis or for organ cultures.
Assessment of trabecular and cortical microarchitecture
mCT (mCT40; Scanco Medical, Basserdorf, Switzerland) was used
to assess trabecular bone volume fraction [bone volume/total
volume (BV/TV)] and microarchitecture in the metaphyseal
region of the tibia and cortical geometry at the midtibia. For
trabecular bone, the BV/TV (%), the trabecular thickness (mm),
the trabecular number [number of plates per unit of length
(mm)], and the trabecular space (mm) were assessed on 100
contiguousmCTslidesstarting100slidesbelowthegrowthplate.
For cortical bone, the average totalarea (TA)inside the periosteal
envelope (mm
2), the bone area (BA) within this same envelope
(mm
2), the marrow area (MA, mm
2), and the average cortical
thickness (mm) were assessed at 6-mm resolution on 54
contiguous mCT slides.
Bone histology and histomorphometry
Tibias and parietal bones werefixed in 4%formaldehyde in0.1M
phosphatebuffer(pH7.2),dehydratedinacetone,andprocessed
for glycol-methacrylate embedding without decalcification.
Histomorphometric measurements were carried out on 5-mm-
thick sections with an interactive image-analysis system (IAS
2000; Delta Sistemi, Rome, Italy) as described previously,
(23,24)
and with the suggested nomenclature.
(25) Osteoclast number/
bone surface (n/mm
2) and osteoclast surface/bone surface (%)
were evaluated after staining the sections for tartrate-resistant
acid phosphatase (TRACP). Osteoblast surface/bone surface (%)
was evaluated after staining the sections with methylene blue/
azure II. Finally, dynamic assessment of the mineral apposition
rate(MAR)wascalculatedafterdoubleinjectionofcalcein10and
3 days before euthanization. All reagents were from 2M
Strumenti (Rome, Italy) and Bio Optica (Milan, Italy).
Patients
The study was approved by the ethical committees of Ospedale
Pediatrico Bambino Gesu `, Rome, Istituto Auxologico Italiano,
Milan, Istituto Neurologico Besta, Milan, and University Hospital
San Salvatore, L’Aquila, Italy. Patients were diagnosed and
followed at Ospedale Pediatrico Bambino Gesu `, Istituto
Auxologico Italiano, and Istituto Neurologico C. Besta, and their
characteristics and clinical parameters are shown in Table 1. The
study was conducted with the informed consent of healthy
donors and patients’ parents and involved collection of human
biologic samples (ie, peripheral blood, serum, urine, and bone
fragments) and dual-energy X-ray absorptiometry (DXA). We
strictly adhered to all current ethical and safety provisions
applicable, in compliance with the Declaration of Helsinki in its
latest version and the regulation of our competent ethical
committees.
Table 1. Characteristics of the Studied Subjects
Subjects N Age Weight Height
Controls 11 8.7 2.7 26.7 2.02 124.0 6.7
Patients 16 8.4 1.9 17.7 3.8 103.0 7.2
Note: Data are expressed as means SD.
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males. Diagnosis was based on clinical data and on molecular,
morphologic, and immunochemical evaluation confirming the
absence of dystrophin in muscle fibers. Patients were not treated
with any glucocorticoid therapy and were not affected by other
diseases that could influence bone metabolism. Control subjects
werematched for age and gender and tested forstandard serum
markers to exclude any inflammatory status.
Bone mass
BMD was evaluated by DXA (Hologic Discovery A in Milan and
Hologic Delphi W in Rome; Hologic, Inc., Waltham, MA, USA) at
the lumbar spine (L2–L4) using the same scanning and analysis
protocol in all centers. A standard adjustment, based on the
approximate bone volume calculated, considering lumbar
vertebral bodies as cylinders, was used. This adjustment gives
a measure called bone mineral apparent density (BMAD).
(26,27)
BMAD was calculated and expressed as a Z-score. The Z-score
was calculated, selecting a reference sample of age-matched
healthy Italian boys from the database of the Istituto Auxologico
Italiano.
Serum markers
Patients’ serum total calcium, phosphorus, bone turnover
markers, and calciotropic hormones were measured using
standard methods. Radioimmunologic assay kits were used to
measure serum osteocalcin (01051950; TechnoGenetics, Milan,
Italy) and 25-hydroxyvitamin D (310600; DiaSorin, Stillwater,
MN, USA). ELISA kits were used to measure urinary N-terminal
telopeptideofprocollagentype1(NTX;OstexIntern, Seattle,WA,
USA) and serum bone alkaline phosphatase (BALP; EIA, Metra
BAP, Quidel, San Diego, CA, USA). Immunoradiometric assay kit
was used to measure N-parathyroid hormone (PTH; 01052410;
TechnoGenetics).Radioreceptorassaywasusedtomeasure1,25-
dihydroxyvitamin D3 (3520; Nichols Institute Diagnostic, San
Juan Capistrano, CA, USA). ELISA kits were used to measure
osteoprotegerin (OPG), serum receptor activator of NF-kB ligand
(sRANKL; kits RD194003200 and RD193004200R; BioVendor,
Candler, NC, USA), as well as interleukin 6 (IL-6), tumor necrosis
factor a (TNF-a), IL-12 p70, IL-11, inhibin-bA, and transforming
growth factor b2 (TGF-b2) (HS600B, HSTA00D, DY1270, D1100,
DAC00B, and DB250; R&D Systems, Minneapolis, MN, USA).
Reagents for the in vitro and animal studies
Cell culture medium, fetal calf serum (FCS), reagents, and Trizol
for RNA extraction were from Invitrogen (Carlsbad, CA, USA).
Sterile glassware was from Falcon Becton Dickinson (Meylan,
France). Cytokines for cell cultures and the blocking antibody
againsthumanandmouseIL-6werefromPepro-Tech(RockyHill,
NJ, USA). Unless otherwise specified, all other reagents were of
the purest grade from Sigma-Aldrich (St Louis, MO, USA).
Mouse serum C-terminal collagen type 1 cross-links (CTX) and
TRACP activity were evaluated in serum and/or in conditioned
medium by ELISA kits from Pantec (AC06F1 and SBTR103, Turin,
Italy), whereas IL-6, sRANKL, and OPG were measured by ELISA
kits from R&D Systems (M6000B, MTR00, and DY459).
Human primary osteoblast cultures
Bone fragments were obtained from healthy subjects who
underwent femoral surgery for traumatic fractures. Bone
fragments were subjected to sequential digestion with 1mg/
mL of Clostridium histolyticum type IV collagenase and 0.25%
trypsin as described previously.
(28) Cells obtained with this
method were positive for alkaline phosphatase (ALP) activity and
expressed the osteoblast markers PTH/PTH-related peptide
receptor, type I collagen, osteocalcin, osteopontin, bone
sialoprotein II, and Runx2.
(28) Osteoblasts were plated in 6-well
multiplates, grown to 80% confluence, then starved for 24hours
in medium with 1% FCS, and subsequently treated with medium
containing 10% human serum from DMD patients or from
healthydonorsfor48hours,inagreementwithpreviouswork.
(29)
Nodule mineralization
Human osteoblasts were grown until 80% confluence. Medium
was replaced with mineralization medium composed of
Dulbecco’s modified Eagle medium (DMEM), 10mM b-glycer-
ophosphate, 50mg/mL of ascorbic acid, and 10% serum from
either healthy donors or DMD patients. Medium was replaced
every 3 days, and cells were cultured for 3 weeks. At the end of
incubation, mineralization was detected by von Kossa staining.
ALP activity
ALP activity was evaluated biochemically using Sigma Kit N1891
or, otherwise, histochemically using Sigma Kit 85L3R in cultured
osteoblasts previously fixed in 4% paraformaldehyde in 0.1M
cacodylate buffer.
Osteoclast preparation from peripheral blood monocytes
Osteoclast precursors were isolated from human peripheral
blood from DMD patients and healthy donors as described
previously
(29) and cultured for 14 days in standard medium
containing 10% FCS in the presence of 25ng/mL of macrophage
colony-stimulating factor (M-CSF) and 30ng/mL of sRANKL. Cells
from healthy donors also were incubated for the same time in
medium containing 10% human serum from DMD patients or
healthy donors in the presence of 25ng/mL of M-CSF and a
suboptimal concentration of sRANKL (0.5ng/mL).
(29) Medium
and factors were replaced every 3 days.
TRACP activity assay
Cells were fixed in 4% paraformaldehyde in 0.1M cacodylate
buffer for 15minutes and washed in the same buffer. TRACP
activity was detected histochemically using Sigma-Aldrich Kit
387-A according to the manufacturer’s instruction.
Comparative real-time RT-PCR
Total RNA was extracted using the Trizol procedure; then 1mg
was reverse transcribed, and the equivalent of 0.1mg was
employed for the PCR reactions using the Brilliant SYBR Green
QPCR Master Mix (Aurogene, Rome, Italy). Primer sequences and
real-time PCR conditions are listed in Supplemental Table S1.
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Total RNA was extracted from human osteoblasts cultured for
48hours in the presence of 10% serum from DMD patients or
from healthy subjects and employed for the real-time PCR array.
Two sets of arrays were used: a panel of osteogenic markers
(human osteogenesis PCR array PAHS-026; Superarray Bio-
sciences, Frederick, MD, USA) and a panel of inflammatory
cytokines (human cytokines PCR array PAHS-021, Superarray
Biosciences). Briefly, c-DNA from osteoblasts was mixed with
a SYBR Green Master Mix (RT
2 SYBR Green qPCR master mix;
PA-012; Superarray Biosciences) and then dispensed in the wells
for the specified panels. Wells were subjected to real-time
PCR (Stratagene MX 3000, La Jolla, CA, USA) following the
manufacturer’s instructions.
Array data analysis
Array data were automatically analyzed by the dedicated
software, RT
2 Profiler PCR Array Data Analysis Template Version
3.2 (Superarray Biosciences). Briefly, the gene expression profiles
from each array were normalized versus a set of 6 housekeeping
genes. Genes from the two sets of data then were distributed by
the threshold cycle values, plotted by two-tailed Student’s t test
that assumes a normal distribution, and filtered by a significance
of p<.05.
Calvarial organ cultures
Calvaria from 4-day-old CD1 mice (Harlan Laboratories, Udine,
Italy) were explanted, dissected free of adjacent connective
tissue, and placed in a modified essential medium (a-MEM)
supplemented with 10% sera from 6-month-old wild-type or
MDX mice and incubated with 1mg/mL of blocking antibody
against IL-6 or with irrelevant IgG as control. After 7 days, con-
ditioned medium was collected for ELISA assay, and bones were
fixed and processed as earlier for histomorphometric analysis.
Statistics
Data distribution was analyzed previously by the Anderson-
Darling test. If normally distributed, data were expressed as the
mean SD of at least three independent experiments or three
animals per group; otherwise, they were expressed as a value
range. Statistical analysis was performed by one-way analysis of
variance, followed by Student’s unpaired t test for the normally
distributed data and by the Wilcoxon test in the other cases.
p Values of less than .05 were considered statistically significant.
Results
Bone phenotype in MDX mice
In MDX mice of both genders, significant bone loss was apparent
at trabecular and cortical levels versus wild-type mice. In
particular, mCT analysis showed a significantly lower bone
volume percentage of the tibial metaphysis in MDX animals
(Table 2, Fig. 1A). At the tibial midshaft, there was an obvious
thinning of the collar in MDX animals compared with wild-type
animals (Table 2, Fig. 1B), with a consequent lower cortical total
area and bone area in both genders as well as a lower cortical
thickness and marrow area in females (Table 2). These
observations demonstrate that the loss of dystrophin causes
an osteopenic phenotype in the MDX mouse model. Therefore,
we investigated the underlying cellular mechanism by examin-
ing osteoclasts and osteoblasts in vivo.
Histochemical analysis showed more intense staining for the
osteoclast-specific marker TRACP lining the growth plate
mineralized cartilage and bone trabeculae in the proximal
spongiosa of the tibias of MDX animals (Fig. 1C). Higher
magnification showed more osteoclasts in MDX mice than in
wild-type mice (Fig. 1C), and histomorphometry confirmed
higher osteoclast surface and osteoclast number per bone
surfaceinthesecondaryspongiosaofMDXversuswild-typemice
in both genders (Table 2). Consistent with the histologic results,
CTX, a marker of in vivo bone resorption, was significantly higher
in MDX mice (Fig. 1D). Staining of bone sections of MDX mice
with methylene blue/azure II demonstrated that the bone
trabecular surface was especially coated by flattened and
presumably less active osteoblasts than in wild-type mice
(Fig. 1E) and that the osteoblast surface per bone surface was
lowerinMDXthaninwild-type miceinbothgenders(Table2).To
investigate dynamically whether osteoblast deficiency had an
impact on ossification, we evaluated the mineral apposition rate
(MAR) by invivodouble fluorescent calcein labelingof trabecular
bone. A 25% less MAR was found at the proximal secondary
spongiosa of MDX mice versus wild-type mice (Table 2, Fig. 1F).
To distinguish between humoral and mechanical influence on
bone structure, we evaluated calvarial bone histology and
histomorphometry because these bones are modestly affected
by mechanical strength. Histomorphometry showed lower bone
volume percentage (Table 2) and higher number of osteoclasts
(Table 2, Fig. 1G)i nMDX compared with wild-type mice.
Interestingly, in a panel of circulating pro-osteoclastogenic
cytokines evaluated in the sera, IL-6 was found to be increased in
MDX mice (5.3-fold) compared with wild-type mice (Fig. 1H).
Surprisingly, and in contrast with the increased osteoclast
activity observed by histomorphometry, sRANKL and, conse-
quently, the sRANKL/OPG ratio were not increased but rather
decreased, although not significantly (p¼.07 and p¼.1,
respectively; Fig. 1I)i nMDX compared with wild-type mice.
Similar results were observed when the RANKL/OPG mRNA ratio
was examined in the femurs of MDX compared with wild-type
mice (Fig. 1J).
Bone density and cytokine imbalance in DMD patients
In agreement with our observations in mice, among the bone
turnover parameters evaluated in 16 patients with DMD before
the onset of treatment with glucocorticoids (Table 3), NTX,a
marker of boneresorption, was higher than normal. Consistently,
the BMAD Z-score was lower than normal. The distribution plot
in Fig. 2 shows that in 6 patients (37%) the BMAD Z-score
was lower than  1. In particular, in 3 of them it was between
 1.1 and  2, and in the other 3 it was below  2.
To assess the involvement of circulating cytokines, our 16
DMD patients and 11 gender- and age-matched healthy controls
were analyzed by ELISA for the serum concentrations of a panel
of cytokines. Notably, IL-6 showed a significant increase in DMD
1894 Journal of Bone and Mineral Research RUFO ET AL.patients compared with healthy subjects (Table 4), consistent
with their low BMAD. sRANKL was 54% lower in DMD sera, and
the sRANKL/OPG ratio was significantly lower in the DMD group
compared with the healthy group. This is similar to our
observations in MDX mice and in sharp contrast with the low
Z-scores and high urinary NTX levels observed in the patients.
Effect of DMD sera on osteoblasts
To address whether imbalance of circulating cytokines can be
involved in the pathogenesis of bone loss in DMD, we analyzed
the effects of DMD sera in cell cultures. To reduce the effects of
variability, pools of equivalent aliquots of the sera from the 16
DMD patients and the 11 control subjects described in Table 1
were used. In these pools, IL-6 concentration was measured and
found to be 4.0 0.4pg/mL in DMD and 1.6 0.1pg/mL in
control sera (p¼.02).
IL-6 is known to be a negative regulator of osteoblasts
(23,30);
therefore, we hypothesized that osteoblast differentiation and
activity could be decreased by DMD sera. To address this
hypothesis, we incubated human primary osteoblasts from
healthy donors with 10% of DMD or healthy sera before assaying
matrix mineralization and testing differentiation markers.
Mineralized nodule formation was decreased in osteoblast
cultures containing sera from DMD patients (Fig. 3A), whereas
the histochemical and biochemical evaluation of ALP showed no
modulation (Fig. 3B). In addition, the mRNA levels of the
osteoblast transcription factor osterix and of the matrix protein
osteocalcin evaluated by real-time RT-PCR were significantly
decreased, whereas Runx2, which is known to be crucial for early
osteoblast differentiation, was not affected (Supplemental
Fig. S1). To assess whether these transcriptional effects were
IL-6-dependent, we incubated the cells in the presence of an IL-
6-blocking antibody and observed that this treatment prevented
the decrease of osterix and ostecalcin mRNA induced by the DMD
sera (Fig. 3C).
To better analyze how osteoblast differentiation and activity
were affected by imbalanced circulating cytokines, we per-
formed real-time RT-PCR arrays to evaluate the transcription
levels ofa panel of osteoblast differentiation markers. A decrease
in many osteogenic factors in osteoblasts cultured with DMD
sera versus control sera, in particular of various bone
morphogenetic proteins (BMPs), was in agreement with the
hypothesized impairment of osteoblast function (Supplemental
Table S2). Taken together, these results suggest that osteoblasts
are disturbed by DMD serum cytokine imbalance, especially at
the late stage of differentiation, and that increased IL-6 may
represent one of the mediators of the observed modulations.
Effect of DMD sera on osteoclastogenesis
Cytokine imbalance in sera suggested that osteoclast formation
also could be changed if peripheral blood precursors were
exposed to DMD sera. To analyze this aspect, peripheral blood
Table 2. Bone Microarchitectural and Histomorphometric Parameters in MDX Mice
Males Females
Wild type MDX p Value Wild type MDX p Value
Trabecular bone, mCT
a
Bone volume/total volume, % 9.2 0.9 5.7 1.1 .04 5.8 0.7 3.5 1.5 .04
Trabecular number
b 4.10 0.11 3.5 0.3 .02 3.0 0.9 2.8 0.9 .23
Trabecular thickness, mm 36.0 2.3 37.0 2.6 .67 42.1 2.2 42.9 4.0 .72
Trabecular space, mm 236.0 7.3 289.0 28.5 .04 320.0 25.0 360.0 46.0 .27
Cortical bone, mCT
Cortical total area, mm
2 0.62 0.04 0.55 0.02 .03 0.57 0.04 0.46 0.05 .02
Cortical bone area, mm
2 0.40 0.01 0.35 0.02 .04 0.37 0.03 0.30 0.02 .03
Cortical marrow area, mm
2 0.22 0.03 0.20 0.01 .23 0.20 0.01 0.16 0.02 .02
Cortical thickness, mm 244.0 13.0 230.0 11.0 .23 238.5 6.9 222.0 7.2 .04
Trabecular bone, histomorphometry
c
Osteoclast surface/bone surface, % 15.9 4.4 27.4 3.7 .03 11.2 4.3 21.2 4.2 .009
Osteoclast number
d 12.8 1.2 21.5 2.5 .006 10.1 3.1 15.0 3.0 .05
Osteoblast surface/bone surface, % 28.9 8.5 19.6 1.9 .05 36.6 3.5 20.4 3.5 .005
Mineral apposition rate, mm/d Not measured Not measured 0.60 0.16 0.45 0.13 .03
Calvarial bone, histomorphometry
e
Bone volume/total volume, % 78.7 2.1 73.3 2.1 .03 79.0 4.9 68.4 3.4 .04
Osteoclast surface/bone surface, % 2.2 1.3 3.8 1.1 .20 15.3 5.1 19.7 3.1 .18
Osteoclast number
d 1.5 0.8 3.4 0.4 .02 10.9 2.8 15.0 1.8 .04
Osteoblast surface/bone surface, % 6.2 0.9 5.4 1.7 .51 7.8 2.6 7.9 2.3 .93
Note: Values are the mean SD of at least 3 animals per group. MDX¼X chromosome-linked muscular dystrophy.
aProximal tibia metaphysis.
bNumber of plates per unit of length (mm).
cProximal tibia metaphysis, 100mm from distal end of growth plate excluding the endocortical surfaces, longitudinal sections.
dNumber of osteoclasts per mm
2 of bone surface.
eCoronal sections.
IL-6 AND BONE IN DUCHENNE MUSCULAR DYSTROPHY Journal of Bone and Mineral Research 1895Fig. 1. Bone phenotype in MDX mice. mCT analysis performed (A) in the tibial proximal spongiosa and (B) in cortical bone of the tibial midshafts of wild-
type and MDX male and female animals. (C) Histochemical detection of the osteoclast-specific marker TRACP (purple) in proximal tibias of wild-type and
MDX mice. Original magnification  2.5 (upper panels) and  10 (lower panels). (D) Detection of C-terminal telopeptide of type 1 collagen (CTX) in MDX sera
byELISA,asspecifiedin‘‘MaterialsandMethods.’’Averagevalueinwild-typemicewas24.5 7.8ng/mL.
 p¼.04versuswildtype.(E)Histologicsectionsof
secondary proximal spongiosa of wild-type and MDX mouse proximal tibias stained with methylene blue/azure II. Original magnification  2.5 (upper
panels) and  40 (lower panels). Red arrows¼active cuboidal osteoblasts; yellow arrows¼inactive flat osteoblasts. ( F) Calcein (green fluorescence) labeling
of secondary proximal spongiosa from wild-type and MDX mice showing the trabecular mineral apposition (distance between the two fluorescent labels,
evidenced by the yellow lines). Original magnification  40. (G) Coronal sections of calvaria from wild-type and MDX mice stained for histochemical
detection of TRACP (purple). Original magnification  2.5 (upper panels) and  10 (lower panels). (H) Detection of IL-6 in wild-type and MDX sera by ELISA.
(I) Detection of sRANKL in wild-type and MDX sera by ELISA. OPG was unchanged in the two genotypes, whereas RANK-L/OPG ratio was reduced in MDX
sera and also shown in panel I.
 p¼.04 versus wild type. (J) RNA was extracted from femurs of 6-month-old MDX and wild-type mice and reverse
transcribed; then cDNA was subjected to comparative real-time PCR using primer pairs and conditions specific for RANKL and OPG. RANK-L/OPG ratio is
shown.
 p¼.003 versus wild type. Values are normalized versus the house keepinggeneGAPDH. All values are the mean SD of at least four sera samples
or three animals per group.
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supplemented with 10% sera from DMD patients or normal
subjects, 25ng/mL of M-CSF, and a suboptimal sRANKL (0.5ng/
mL) for 14 days.
(29) Interestingly, significant enhancement of
osteoclastogenesis was noted with patients’ sera compared with
healthy sera (2.3-fold), as evidenced by quantification of TRACP
þ
multinucleated cells (Fig. 3D). Moreover, circulating mononucle-
ar precursors from DMD patients showed a parallel higher
osteoclast-forming ability than those from matched normal
donors (1.4-fold; Fig. 3E), suggesting that imbalanced cytokines
especially could affect the number of osteoclast precursors in
DMD patients.
To explain how osteoclast formation could be enhanced
notwithstanding the low circulating sRANKL/OPG ratio previous-
ly described, we hypothesized alterations of some other factors
normally involved in the osteoblast-osteoclast cross-talk. To this
end, we performed real-time RT-PCR arrays on human primary
osteoblasts from healthy donors incubated with 10% of DMD or
healthy sera for 48hours to evaluate the transcription level of a
cytokine panel. Among the few upregulated mRNAs (Table 5),
IL11 was the most increased (>4-fold), followed by inhibin-bA,
IL6, and TGFb2. However, IL-11 was not detectable in both DMD
and healthy sera, whereas measurements of inhibin-bA and TGF-
b2 revealed no difference between DMD and healthy sera
(inhibin-bA: control 256.0 61.0pg/mL; DMD 237.0 74.0pg/
mL; TGF-b2: control 123.0 91.0pg/mL; DMD 117.0 54.0pg/
mL;differencesnotsignificant),thuspointingoutthattheireffect
could be exerted only locally in the bone microenvironment in
response to systemic factors. On the contrary, the IL6 mRNA
increase in osteoblasts cultured with DMD sera was similar to the
increase of its circulating level in patients (>2-fold).
Among the many downregulated cytokine mRNAs (Supple-
mental Table S3), we found several members of the IL-1
superfamily: IL2, IL3, IL4, and TNFa˙ This latter was claimed to be
implicated in the inflammation of DMD patients
(12) but in our
assays appeared undetectable in the circulation of DMD patients
(Table 4) and strongly downregulated in osteoblasts treated with
the DMD sera (86% less compared with healthy sera;
Supplemental Table S3).
Expression of selected genes from the RT-PCR array also was
validated by standard real-time RT-PCR (Fig. 4A). In addition, by
real-time RT-PCR we evaluated the transcriptional expression
of RANKL and OPG, which were not included in the osteoblast
cytokine array. We again observed downregulation of RANKL
mRNA (88% less compared with healthy sera) and no
significant change in OPG mRNA, with a subsequent
decrease in the osteoblast RANKL/OPG ratio (80% less than in
healthy sera; Fig. 4A), in agreement with the reduced
protein ratio shown previously in MDX and DMD sera
(Fig. 1 and Table 4).
To assess whether the earlier described most upregulated
cytokines with osteoclastogenic potential were able to
increase osteoclastogenesis in the absence of sRANKL, we
performed healthy-donor peripheral blood mononuclear cell
cultures incubated for 14 days in the presence of 25ng/mL of
M-CSF and 10ng/mL of human recombinant IL-6, inhibin-bA,
IL-11, or TGF-b2, alone or in combination, and compared
the results with the same concentration of sRANKL. Induction
of osteoclastogenesis was evident for all these cytokines
relative to M-CSF alone (Fig. 4B). Interestingly, the effects
of the four cytokines in combination did not appear to be
additive, consistent with convergence on common intracellular
pathways. Altogether, these results highlight that imbalanced
osteoclastogenic cytokines could be responsible of enhanced
osteoclast formation even in the event of reduced sRANKL/OPG
levels.
Table 3. Bone Turnover Parameters in Sera of DMD Patients
Marker DMD patients Normal ranges
Serum Ca (mg/dL) 10.0 0.37 8.4–10.4
Serum P (mg/dL) 5.4 0.49 3.5–5.5
Serum Mg (mg/dL) 2.3 0.17 1.6–2.9
Serum Cr (mg/dL) 0.24 0.07 0.2–1.0
Urinary NTX (nMBCE/mMCR) 498 139 60–380
Serum OCN (ng/mL) 60 14 5–76
Serum BALP (U/L) 63 3.8 14.2–72.7
Serum PTH (pg/mL) 31 14 20–59
Serum 25(OH)D (ng/mL) 20 15 20–60
Serum 1,25(OH)2D3 (pg/mL) 36 12 26–49
Note:Dataareexpressedasmeans SD.Ca¼calcium;P¼phosphorus;
Mg¼magnesium; Cr¼creatinine ; BALP¼bone alkaline phosphatase;
OCN¼osteocalcin; PTH¼parathyroid hormone; 25(OH)D¼25-hydroxi-
vitamin D; 1,25(OH)2D3¼1,25-dihydroxivitamin D3.
Fig. 2. Distribution of the 16 DMD patients along the bone mineral
apparent density (BMAD) Z-score gradient.
Table 4. Serum Cytokine Levels in DMD Patients
Cytokine Healthy subjects DMD patients p Value
IL-6, pg/mL 1.93 1.38 3.77 2.71 .04
TNF-a, pg/mL Not detectable Not detectable —
IL-12 p70, pg/mL Not detectable Not detectable —
sRANKL, pM 51–457
a 10–302
a .007
OPG, pM 3.4 1.3 4.0 1.3 NS
sRANKL/OPG 15–163
a 1.8–107
a .005
Note: Data are expressed as means SD or as a range. p Value indicates
the significance level. NS¼not significant.
aThesedataarenotnormallydistributed,asevaluatedbytheAnderson-
Darling test. Therefore, they are expressed as value ranges.
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healthy donors (Control) or DMD patients and with ascorbic acid and b-glycerophosphate, as described in ‘‘Materials and Methods,’’ to favor
mineralization. Cultures then were fixed and stained to reveal mineralized nodules by the von Kossa reaction (dark staining, panels). Intensity of
mineralization was measured by densitometry (graphs).
 p¼.0005 versus control. (B) Osteoblasts were grown as above and then evaluated for alkaline
phosphatase (ALP) activity by histochemical detection (panels, dark staining) or by biochemical detection (graphs). (C) Osteoblasts were grown in the
presence of 10% sera pooled from healthy controls or DMD patients, with an IL-6-blocking antibody (IL-6 Ab) or an irrelevant IgG, as indicated. After
48hours,RNA was extractedand reversetranscribed, andcDNAwas subjectedto comparative real-timePCR usingprimerpairs andconditionsspecific for
osterix (OSX), osteocalcin (OCN) and Runt-related transcription factor 2 (RUNX2).
#p¼.004 and
 p¼.0005 versus control. (D) Human peripheral blood
mononuclear cells from healthy donors were cultured in the presence of 25ng/mL of M-CSF, 0.5ng/mL of sRANKL, and 10% sera from healthy donors
(Control) or DMD patients and evaluated for TRACP positivity, as described in ‘‘Materials and Methods.’’
 p¼.003 versus control. (E) Human peripheral
blood mononuclear cells from control subjects or 3 DMD patients were cultured in the presence of 10% FBS, 25ng/mL of M-CSF, and 30ng/mL of sRANKL
and evaluated for TRACP positivity, as described in ‘‘Materials and Methods.’’
#p¼.05 versus control. Average numbers of TRACP
þ multinucleated
osteoclasts under control conditions was 29.8 19.4/well in panel D and 36.0 10.2/well in panel E. All values are the mean SD of at least three
independent experiments. Original magnification  10.
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antibody
To assess whether, among the imbalanced cytokines, circulating
IL-6 played a dominant role in osteoclast formation and to
further support a translational meaning of our observations, we
cultured ex vivo calvarial bones excised from wild-type neonatal
mice in the presence of 10% sera from wild-type or MDX mice
with or without an IL-6-blocking antibody. We observed that the
bone-resorption parameter CTX and the osteoclast parameter
TRACP were increased significantly in the medium in the
presence of MDX sera compared with wild-type sera, and in both
conditions, treatment with the blocking antibody reduced these
biomarkers (Fig. 5A, B). This was in agreement with the
histomorphometric evaluation of the osteoclast surface and
number (Fig. 5C, D, G). In this circumstance, as shown by
osteocalcin detection in the medium (Fig. 5E) and histomorpho-
metric evaluation in the sections (Fig. 5F, G), osteoblast
parameters were not affected, possibly owing to the short-term
treatment performed in our experiments. These results suggest
an impact of systemic IL-6 on the osteoclast and bone-resorption
parameters that could be blocked by anti-IL-6 treatment.
Discussion
Altogether, our results suggest that the defective bone mass in
DMD is secondary not only to the failure in muscular traction but
also to the marked uncoupling of osteoclast and osteoblast
activity potentially caused by imbalanced circulating and local
cytokines, among which we point to IL-6 as a crucial systemic
mediator of bone loss.
(23) These results are in keeping with a
recent report by Nakagaki and colleagues,
(31) who demonstrated
reduced bone mass and altered bone mechanical and
biochemical properties in MDX mice at 21 days of life, when
histologic sections and Evans blue staining showed no muscle
fiber damage, but are in disagreement with Montgomery
and colleagues,
(32) who evidenced increased femoral BMD in
4-month-old MDX mice.
Inflammation and inflammatory cells present in DMD muscles
play an important role in generating atrophy and in inhibiting
regeneration, therefore promoting progression of muscle
damage,
(33) but the exact inflammatory mechanisms and the
pivotal inflammatory molecules involved so far are not known.
There is now evidence that the bone tissue is also significantly
affected in DMD and that low bone mass and increased
frequency of fractures may be complications even at an early
stage of the disease.
(18–22,34) Many cytokines and other local
regulators are involved in the control of bone remodeling with a
highdegreeofredundancy,
(35,36)andmanycelltypestakepartin
this process, including osteoblasts, osteoclasts, inflammatory
cells, and cells of the immune system.
(37,38)
Skeletal muscle has been identified recently as an endocrine
organ producing a number of ‘‘myokines‘‘ belonging to different
cytokine families, and IL-6 was discovered as a myokine because
it systemically increases during physical exercise.
(39,40) Interest-
ingly, IL-6 also has been observed to be increased in dystrophic
muscles
(41) and therefore may represent one of the mediators of
the bone phenotype in DMD. IL-6 plays a crucial role in bone
metabolism, especially in nonphysiologic conditions. In fact, it
has been shown that chronically increased systemic levels of IL-6
induce significant bone loss in growing IL-6 transgenic mice
(23)
and that chronically elevated IL-6 is associated with bone loss in
postmenopausal and juvenile osteoporosis.
(42,43) This cytokine
also has been implicated in the pathogenesis of osteolysis
associated with Paget disease,
(44) multiple myeloma,
(45,46)
Gorham-Stout disease,
(47) and juvenile idiopathic arthritis.
(48)
Our work demonstrates that IL-6 is involved in the bone
phenotype of both DMD patients and MDX mice. An extensive
analysis of osteogenic markers in osteoblasts exposed to DMD
sera showed an overall downregulation of many transcripts,
consistently with the poor ability of these cells to mineralize the
bone matrix. Specifically, bone morphogenetic protein 4 (BMP-4)
and BMP-6, which showed about 60% and 80% decrease,
respectively, are known to strongly stimulate osteoblastogen-
esis,
(49,50) whereas osterix and osteocalcin are osteoblast genes
implicated in osteoblast maturation and bone formation.
(51)
Among the other modulated transcripts, most are not yet clearly
correlated with osteoblast differentiation. Nevertheless, amelo-
genin and enamelin, for example, which are known to be crucial
in dental matrix maturation,
(52,53) seem to correlate with the
lower ability of osteoblasts to fully comply with their functions.
Taken together, these data suggest an effect of DMD circulating
factorsonlatestageofosteoblastdifferentiationandsubsequent
matrix defects. The blunting effect of IL-6-neutralizing antibody
was observed in these cultures, supporting a role of this cytokine
in the impaired activity of osteoblasts.
In addition, osteoclast precursors were affected by DMD and
MDX sera. In both circumstances, we observed an increase of
osteoclastogenesis. This result is again in agreement with the
increase in circulating IL-6 because it was able alone to induce
osteoclastogenesis in vitro in the absence of sRANKL. Moreover,
an extensive analysis of many cytokines expressed by
osteoblasts exposed to DMD sera revealed a notable upregula-
tion of several local factors potentially able to stimulate
osteoclastogenesis, which, however, were not observed to be
changed systemically in the circulation. Among them, IL-11 is
already known to promote osteoclast maturation and bone
resorption in bone marrow cultures,
(54,55) and inhibin-bA was
associated recently with induction of osteoclastogenesis in the
absence of RANKL.
(56) Interestingly, among the downregulated
cytokines, TNF-a, which could be involved in the inflammation
Table 5. Cytokines Upregulated in Osteoblasts Treated With
DMD Sera
Gene name Gene symbol Fold change p Value
Interleukin 11 IL11 4.1 0.13 .00003
Inhibin-bA INHBA 3.1 0.15 .03
Interleukin 6 IL6 2.2 0.26 .003
Transforming
growth factor b2
TGFB2 2.0 0.24 .002
Note: Fold change represents the gene expression ratio between
osteoblasts incubated with patient sera and control sera, respectively,
and is expressed as mean SD of three independent experiments. p
Value indicates the significance level.
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(12) was not detectable in
DMD patient sera. Also, in MDX mice, the osteopenic/osteopo-
rotic bone phenotype appeared to be caused by an imbalance
between osteoblast and osteoclast activity. In fact, especially the
osteoclast lineage also was affected in calvaria, in which
mechanical loading is negligible, so confirming a potential
involvementofcirculatingcytokinesaffectingthesecells.Among
these potential mediators, IL-6 appears to be a pivotal factor not
only in humans but also in mice because an IL-6-blocking
antibody preventedthe increaseinosteoclastformation induced
by MDX sera in calvarial organ cultures.
The role of IL-6 in the DMD bone disease may open new
therapeutic perspectives based on anti-IL-6-receptor therapy. An
IL-6 receptor inhibitor (humanized monoclonal antibody to the
IL-6receptor,tocilizumab)isalreadyinclinicaltrialsforchildhood
inflammatory diseases.
(57) Unfortunately, to the best of our
Fig. 4. Cytokineexpressionandosteoclastogenesisassay.(A)OsteoblastsfromhealthydonorswereincubatedwithserafromcontrolsorDMDpatients,as
described in ‘‘Materials and Methods.’’ RNA was extracted and reverse transcribed, and cDNA was subjected to comparative real-time PCR using primer
pairs and conditions specific for inhibin-bA (INHBA), IL11, TGFb2, TNFa, bone morphogenic protein 6 (BMP6), BMP7, RANKL, and OPG. RANKL/OPG ratio is also
shown.
#p¼.02;
88p¼.03;
 p¼.04;
8p¼.002; and
##p¼.003 versus control. Values are normalized versus the housekeeping gene GAPDH. (B) Human
peripheral blood mononuclear cells from healthy donors were cultured, as described in ‘‘Materials and Methods,’’ in the presence of M-CSF and 10ng/mL
of IL-6, IL-11, inhibin-bA, TGF-b2, or sRANKL as positive control. TRACP
þ multinucleated cells were enumerated and expressed as fold increase of control.
Average numbers of osteoclasts in control conditions (Vehicle) was 19.0 6.0/well.
  p¼.02;
 p¼.04;
#p¼.007;
##p¼.003; and
8p¼.0007 versus control.
All values are the mean SD of three independent experiments.
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receptor–neutralizingantibodyisfrom ratandcanbeusedsolely
in mice in short-term experiments because it stimulates an
immune response and is rapidly inactivated. This prevented us
from performing long-term treatments necessary to unveil a
positive effect on bone in MDX mice. However, and consistent
with our hypothesis, treatment with commercially available IL-6-
blocking antibodies prevented the effects of dystrophic sera
both on mouse and human bone. Therefore, we deem that this
observation could have a translational impact and could open a
new avenue for the treatment of bone disease in DMD patients
with anti-IL-6 therapy.
In conclusion, we believe that our work provides an
understanding of the molecular and cellular aspects of bone
loss in DMD and a rationale for new therapies to maintain the
bone structure and improve bone strength, which may, in turn,
contribute to a better quality of life in DMD patients.
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